Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biopharma leader advancing CRISPR-engineered allogeneic CAR-T cell therapies. This page aggregates official announcements, clinical trial milestones, and strategic developments related to its chRDNA technology platform.
Investors and researchers will find timely updates on Caribou's innovative pipeline programs targeting hematologic cancers and autoimmune diseases. Key focus areas include CB-010 for B-cell malignancies, CB-011 in multiple myeloma, and autoimmune applications of PD-1 knockout therapies.
The repository features press releases on clinical trial data, regulatory progress, intellectual property developments, and strategic collaborations. Content is organized to highlight scientific advancements while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Caribou's latest CRISPR innovations and corporate announcements. Check regularly for updates on allogeneic cell therapy developments and their potential impact on treatment paradigms.
Caribou Biosciences (CRBU) announced a strategic pipeline prioritization focusing on its lead oncology programs CB-010 and CB-011, with clinical data disclosures now planned for H2 2025. The company is implementing workforce and cost reduction initiatives, including a 32% workforce reduction, expected to extend cash runway into H2 2027.
Key updates include:
- CB-010 ANTLER trial: Plans to present data from 20-patient confirmatory cohort with 6+ months follow-up for 2L LBCL
- CB-011 CaMMouflage trial: Will share dose escalation data from minimum 25 patients with 3+ months follow-up for r/r MM
- Discontinuing GALLOP Phase 1 trial (CB-010 for lupus), AMpLify Phase 1 trial (CB-012 for AML), and preclinical research
- Reduction in force costs estimated at $2.5-3.5 million
- Preliminary cash position of $212.5 million as of March 31, 2025
Caribou Biosciences (NASDAQ: CRBU) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company ended 2024 with $249.4 million in cash and equivalents, expected to fund operations into H2 2026.
Key financial metrics include:
- Q4 2024 revenue: $2.1 million
- Full year 2024 revenue: $10.0 million
- Q4 2024 net loss: $35.5 million
- Full year 2024 net loss: $149.1 million
The company anticipates two major clinical data releases in H1 2025: results from the ANTLER Phase 1 trial of CB-010 in second-line large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The company is advancing four clinical programs across hematologic malignancies and autoimmune diseases.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its upcoming participation in two major investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will be featured in fireside chats at both events.
The schedule includes:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 11:30 AM ET
- Leerink Global Healthcare Conference on March 11, 2025, at 1:40 PM ET
Both presentations will be available via webcast on the company's website, accessible for at least 30 days following each event.
Caribou Biosciences (CRBU) has initiated the GALLOP Phase 1 trial evaluating CB-010 in lupus patients and provided updates across its clinical programs. The company achieved significant progress in 2024, with key developments including the completion of dose level 3 in the CB-012 AMpLify trial for AML with no DLTs.
Multiple clinical data readouts are expected in H1 2025, including CB-010 ANTLER trial data in second-line and CD19 relapsed large B cell lymphoma, and CB-011 dose escalation data in multiple myeloma. The company plans to initiate a pivotal Phase 3 trial for CB-010 in H2 2025, pending confirmation of their HLA matching strategy.
With $281 million in cash as of September 30, 2024, Caribou expects to fund operations into H2 2026. The company recently strengthened its leadership team with key appointments, including Sri Ryali as CFO.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Rachel Haurwitz, PhD, the company's president and CEO, will deliver a corporate update presentation on Thursday, January 16, 2025, at 10:30 am PST.
The presentation will be accessible via webcast through the Events page on Caribou's website, with recordings remaining available for 30 days following the event.
Caribou Biosciences (Nasdaq: CRBU) has appointed Sri Ryali as Chief Financial Officer, effective immediately. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry and will lead corporate finance, investor relations, and corporate communications functions, reporting to CEO Rachel Haurwitz.
Ryali previously served as CFO of Codexis and Eiger BioPharmaceuticals, and held senior finance positions at Aimmune Therapeutics, Onyx Pharmaceuticals, and Amgen. He holds an MBA from UCLA Anderson School of Management and a BA in economics and microbiology from UCLA.
The appointment comes at a important time as Caribou advances four clinical-stage programs for hematologic malignancies and autoimmune diseases, with multiple datasets expected to be disclosed in 2025. The company focuses on developing off-the-shelf CAR-T cell therapies using CRISPR genome-editing technology.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in two upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will join a panel on cell therapies in autoimmune disorders at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 2:30 PM EST. She will also participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 10:25 AM EST. Webcasts of both events will be available on Caribou's website for 30 days following the presentations.
Caribou Biosciences reported Q3 2024 financial results, highlighting progress across four clinical-stage programs. The company reported a net loss of $34.7 million and revenue of $2.0 million. Cash position stands at $281.0 million, expected to fund operations into H2 2026. Key developments include advancing CB-010 for LBCL and lupus, CB-011 for multiple myeloma with encouraging efficacy observations, and CB-012 for AML. The company received Fast Track designations for CB-010 and CB-012, and plans multiple clinical data reports throughout 2025.
Caribou Biosciences, Inc. (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024. The event will be held from November 14-19, 2024, in Washington, DC.
The poster will present preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance for evaluating CB-010 in the GALLOP Phase 1 clinical trial. This trial focuses on patients with lupus nephritis (LN) and extrarenal lupus (ERL).
The presentation, titled 'Preclinical Analysis of CB-010, an Allogeneic anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE),' will be delivered by Elizabeth Garner, PhD, on November 16, 2024.
Caribou Biosciences (Nasdaq: CRBU) announced that the FDA granted Fast Track designations to two of its therapies: CB-010 for refractory systemic lupus erythematosus (SLE) and CB-012 for relapsed or refractory acute myeloid leukemia (r/r AML). CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial for lupus nephritis and extrarenal lupus, set to begin by year-end 2024. CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, is currently being evaluated in the ongoing AMpLify Phase 1 clinical trial for r/r AML. These designations highlight the significant unmet medical needs and the potential of Caribou's off-the-shelf CAR-T cell therapies.
